214 related articles for article (PubMed ID: 18955450)
1. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
[TBL] [Abstract][Full Text] [Related]
2. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance.
Mann GB; Kang YC; Brand C; Ebeling PR; Miller JA
J Clin Oncol; 2009 Aug; 27(22):3605-10. PubMed ID: 19546403
[TBL] [Abstract][Full Text] [Related]
3. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
5. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of osteoporosis in women with a history of breast carcinoma.
Van Poznak C; Sauter NP
Cancer; 2005 Aug; 104(3):443-56. PubMed ID: 15968687
[TBL] [Abstract][Full Text] [Related]
8. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
9. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
10. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
[TBL] [Abstract][Full Text] [Related]
11. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
13. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Gibson K; O'Bryant CL
J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
[TBL] [Abstract][Full Text] [Related]
14. Low bone density in breast cancer survivors in Korea: prevalence, risk factors and associations with health-related quality of life.
Kim SH; Cho YU; Kim SJ; Lee JE; Kim JH
Eur J Oncol Nurs; 2013 Apr; 17(2):196-203. PubMed ID: 22898655
[TBL] [Abstract][Full Text] [Related]
15. The causes and treatment of bone loss associated with carcinoma of the breast.
Lester J; Dodwell D; McCloskey E; Coleman R
Cancer Treat Rev; 2005 Apr; 31(2):115-42. PubMed ID: 15847981
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Hadji P
Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
[TBL] [Abstract][Full Text] [Related]
17. The management of secondary osteoporosis.
Kelman A; Lane NE
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1021-37. PubMed ID: 16301195
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: a retrospective study.
Odabasi E; Turan M; Tekbas F; Kutlu M
Arch Gynecol Obstet; 2009 Jun; 279(6):863-7. PubMed ID: 19020888
[TBL] [Abstract][Full Text] [Related]
19. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
